期刊文献+

Risk factors for retinopathy associated with interferonα-2b and ribavirin combination therapy in patients with chronic hepatitis C 被引量:4

Risk factors for retinopathy associated with interferonα-2b and ribavirin combination therapy in patients with chronic hepatitis C
下载PDF
导出
摘要 AIM: To elucidate the frequency and risk factors for retinopathy in patients with chronic hepatitis C who are treated by interferon-ribavirin combination therapy. METHODS: We prospectively analyzed 73 patients with histologically confirmed chronic hepatitis C, who underwent combination therapy for 24 wk. Optic fundi were examined before, and 2, 4, 12 and 24 wk alter the start of combination therapy. RESULTS: Fourteen patients (19%) developed retinopathy, which was initially diagnosed by the appearance of a cotton wool spot in 12 patients. Retinal hemorrhage was observed in 5 patients. No patient complained of visual disturbance. Retinopathy disappeared in 9 patients (64%) despite the continuation of combination therapy. However, retinopathy persisted in 5 patients with retinal hemorrhage. A comparison of the clinical background between the groups with and without retinopathy showed no significant differences in age, gender, viral genotype, RNA level, white blood cell count, platelet count, prothrombin time, complications by diabetes mellitus or hypertension, or pretreatment arteriosclerotic changes in the optic fundi. However, multiple logistic regression analysis revealed that complication by hypertension was observed with a high frequency in the group with retinopathy (P = 0.004, OR = 245.918, 95% CI = 5.6-10786.2).CONCLUSION: Retinopathy associated with combination therapy of interferon α-2b and ribavirin tends to develop in patients with hypertension. AIM: To elucidate the frequency and risk factors for retinopathy in patients with chronic hepatitis C who are treated by interferon-ribavirin combination therapy. METHODS: We prospectively analyzed 73 patients with histologically confirmed chronic hepatitis C, who underwent combination therapy for 24 wk. Optic fundi were examined before, and 2, 4, 12 and 24 wk after the start of combination therapy. RESULTS: Fourteen patients (19%) developed retinopathy, which was initially diagnosed by the appearance of a cotton wool spot in 12 patients. Retinal hemorrhage was observed in 5 patients. No patient complained of visual disturbance. Retinopathy disappeared in 9 patients (64%) despite the continuation of combination therapy. However, retinopathy persisted in 5 patients with retinal hemorrhage. A comparison of the clinical background between the groups with and without retinopathy showed no significant differences in age, gender, viral genotype, RNA level, white blood cell count, platelet count, prothrombin time, complications by diabetes mellitus or hypertension, or pretreatment arteriosclerotic changes in the optic fundi. However, multiple logistic regression analysis revealed that complication by hypertension was observed with a high frequency in the group with retinopathy (P = 0.004, OR=245.918, 95% CI=5.6-10786.2). CONCLUSION: Retinopathy associated with combination therapy of interferon a-2b and ribavirin tends to develop in patients with hypertension.
出处 《World Journal of Gastroenterology》 SCIE CAS CSCD 2006年第23期3756-3759,共4页 世界胃肠病学杂志(英文版)
关键词 RETINOPATHY RIBAVIRIN Chronic hepatitis C INTERFERON 视网膜病 干扰素α-2b 病毒唑 丙型病毒肝炎
  • 相关文献

参考文献17

  • 1[1]Hepatitis C-global prevalence (update).Wkly Epidemiol Rec 1999; 74:425-427 被引量:1
  • 2[2]Strader DB,Wright T,Thomas DL,Seeff LB.Diagnosis,management,and treatment of hepatitis C.Hepaology 2004; 39:1147-1171 被引量:1
  • 3[3]Quesada JR,Talpaz M,Rios A,Kurzrock R,Gutterman JU.Clinical toxicity of interferons in cancer patients:a review.JClin Oncol 1986; 4:234-243 被引量:1
  • 4[4]Hayasaka S,Fujii M,Yamamoto Y,Noda S,Kurome H,Sasaki M.Retinopathy and subconjunctival haemorrhage in patients with chronic viral hepatitis receiving interferon alfa.Br J Ophthalmol 1995; 79:150-152 被引量:1
  • 5[5]Sugano S,Suzuki T,Watanabe M,Ohe K,Ishii K,Okajima T.Retinal complications and plasma C5a levels during interferon alpha therapy for chronic hepatitis C.Am J Gastroenterol 1998;93:2441-2444 被引量:1
  • 6[6]Kawano T,Shigehira M,Uto H,Nakama T,Kato J,Hayashi K,Maruyama T,Kuribayashi T,Chuman T,Futami T,Tsubouchi H.Retinal complications during interferon therapy for chronic hepatitis C.Am J Gastroenterol 1996; 91:309-313 被引量:1
  • 7[7]Saito H,Ebinuma H,Nagata H,Inagaki Y,Saito Y,Wakabayashi K,Takagi T,Nakamura M,Katsura H,Oguchi Y,Ishii H.Interferon-associated retinopathy in a uniform regimen of natural interferon-alpha therapy for chronic hepatitis C.Liver 2001; 21:192-197 被引量:1
  • 8[8]Cuthbertson FM,Davies M,McKibbin M.Is screening for interferon retinopathy in hepatitis C justified? Br J Ophthalmol 2004; 88:1518-1520 被引量:1
  • 9[9]Schulman JA,Liang C,Kooragayala LM,King J.Posterior segment complications in patients with hepatitis C treated with interferon and ribavirin.Ophthalmology 2003;110:437-442 被引量:1
  • 10[10]Jain K,Lam WC,Waheeb S,Thai Q,Heathcote J.Retinopathy in chronic hepatitis C patients during interferon treatment with ribavirin.Br J Ophthalmol 2001; 85:1171-1173 被引量:1

同被引文献12

  • 1European Association for the Study of the Liver.EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection[J]. Journal of Hepatology . 2012 (1) 被引量:62
  • 2Paul Y Kwo,Eric J Lawitz,Jonathan McCone,Eugene R Schiff,John M Vierling,David Pound,Mitchell N Davis,Joseph S Galati,Stuart C Gordon,Natarajan Ravendhran,Lorenzo Rossaro,Frank H Anderson,Ira M Jacobson,Raymond Rubin,Kenneth Koury,Lisa D Pedicone,Clifford A Brass,Eirum Chaudhri,Janice K Albrecht.Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial[J].The Lancet.2010(9742) 被引量:3
  • 3Peter Ferenci.Safety and efficacy of treatment for chronic hepatitis C with a focus on pegylated interferons: the backbone of therapy today and in the future[J].Expert Opinion on Drug Safety.2011(4) 被引量:1
  • 4Nilesh Mehta,Uma K. Murthy,Vivek Kaul,Samuel Alpert,Gerald Abruzzese,Charles Teitelbaum.Outcome of Retinopathy in Chronic Hepatitis C Patients Treated with Peginterferon and Ribavirin[J].Digestive Diseases and Sciences.2010(2) 被引量:1
  • 5Ei Tae Kim,Lee Hoo Kim,Jung Il Lee,Hee Seung Chin.Retinopathy in hepatitis C patients due to combination therapy with pegylated interferon and ribavirin[J].Japanese Journal of Ophthalmology.2009(6) 被引量:1
  • 6A.Nadir,A.Amin,N.Chalisa,D. H.Van Thiel.Retinal vein thrombosis associated with chronic hepatitis C: a case series and review of the literature[J].Journal of Viral Hepatitis.2008(6) 被引量:1
  • 7Nezam Afdhal.The Natural History of Hepatitis C[J].Semin Liver Dis (S ).2004(S2) 被引量:1
  • 8Joel A Schulman,Chanping Liang,Lakshmana M Kooragayala,John King.Posterior segment complications in patients with hepatitis C treated with interferon and ribavirin[J].Ophthalmology.2003(2) 被引量:1
  • 9Shigeo Sugano,Tokuya Suzuki,Manabu Watanabe,Kenji Ohe,Kunihiko Ishii,Tugio Okajima.Retinal complications and plasma C5a levels during interferon alpha therapy for chronic hepatitis C[J].The American Journal of Gastroenterology.1998(12) 被引量:1
  • 10胡晓英,高曼.应用干扰素后出现的视网膜病变三例[J].中华眼科杂志,2010,46(9):841-843. 被引量:2

引证文献4

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部